Aktienanalyse zu Evolus Inc (EOLS)EOLSEvolus Inc

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Evolus Inc is currently not a strong buy due to recent negative catalysts and technical indicators, despite some positive fundamentals. The current price is $7.10, with an RSI of 33.516 indicating oversold conditions, but the stock has seen a 5-day change of -8.15%. The negative sentiment from the FDA warning about misleading promotions has impacted the stock significantly, and insider selling has increased by 770.69%.

4 analysts cover EOLS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 19.25.